Ocrevusa 300 mg Concentrate solution for infusion
PDF Leaflet Revision Date: 27 August 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of relapsing and primary progressive multiple sclerosis.
Dosage (summary)
Initial: 600 mg IV (2 infusions of 300 mg, 2 weeks apart); Subsequent: 600 mg IV every 6 months.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; use contraception during treatment and for 6 months after.
Key Drug Interactions
- Live vaccines contraindicated
- Immunosuppressants may increase infection risk
Contraindications
- Hypersensitivity to ocrelizumab
- Active hepatitis B or C
- Active infections
- Live attenuated vaccines
Common side effects
- Infusion-related reactions
- Upper respiratory tract infections
- Nasopharyngitis
Counselling Points
- Premedicate with steroids and antihistamines
- Monitor for IRRs post-infusion
- Avoid live vaccines
Serious warnings
- Risk of PML
- Hepatitis B reactivation
- Monitor for infusion-related reactions
Important Disclaimer
The Ocrevusa 300 mg Concentrate solution for infusion professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
